Volumetric tumor growth in advanced NSCLC patients with EGFR mutations during EGFR-TKI therapy: Developing criteria to continue therapy beyond RECIST progression

PURPOSE: Define volumetric tumor growth rate in advanced NSCLC patients with sensitizing EGFR mutations initially treated with EGFR-TKI therapy beyond progression. METHODS: The study included 58 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, w...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Nishino, Mizuki, Dahlberg, Suzanne E., Cardarella, Stephanie, Jackman, David M., Rabin, Michael S., Ramaiya, Nikhil H., Hatabu, Hiroto, Jänne, Pasi A., Johnson, Bruce E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3817609/
https://ncbi.nlm.nih.gov/pubmed/23922022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28290
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky